NCT06797661 Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions.
| NCT ID | NCT06797661 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasme University Hospital |
| Condition | Glioblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-02-17 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-02-17 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurovascular uncoupling (NVU) represents a major source of potential bias for the identification of eloquent brain regions through activation procedures in blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI). Same region shows proper pattern in glucose metabolism in victiny of brain lesions, investigated with positron emitted tomography with radiolabeled glucose (PET-FDG) This research project aims at investigating the mechanisms of NVU by using a multimodal noninvasive imaging approach in neurosurgical patients.
Eligibility Criteria
Inclusion Criteria: * patients in the study include prior imaging showing a potentially resectable intra-cerebral mass lesion. Patient has to be included before surgery, chemotherapy and radiation Exclusion Criteria: * previous brain surgery * respiratory failure * Asthma * Claustrophobia * Previous adverse reaction to gadovist (contrast agent) * Pregnancy and Breath feeding * Diabetes (type I and II)
Contact & Investigator
Xavier De Tiège, MD,PhD
STUDY CHAIR
Laboratoire de Neuroanatomie et Neuroimagerie translationnelles Université Libre de Bruxelles
Frequently Asked Questions
Who can join the NCT06797661 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06797661 currently recruiting?
Yes, NCT06797661 is actively recruiting participants. Contact the research team at thibault.vanbutsele@hubruxelles.be for enrollment information.
Where is the NCT06797661 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06797661 clinical trial?
NCT06797661 is sponsored by Erasme University Hospital. The principal investigator is Xavier De Tiège, MD,PhD at Laboratoire de Neuroanatomie et Neuroimagerie translationnelles Université Libre de Bruxelles. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.